Compare RLAY & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLAY | MMED |
|---|---|---|
| Founded | 2015 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.1B |
| IPO Year | 2020 | 2026 |
| Metric | RLAY | MMED |
|---|---|---|
| Price | $20.01 | $15.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $19.50 | ★ $22.56 |
| AVG Volume (30 Days) | ★ 4.2M | 1.1M |
| Earning Date | 05-05-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,355,000.00 | N/A |
| Revenue This Year | N/A | $15.99 |
| Revenue Next Year | $324.03 | $10.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.44 | N/A |
| 52 Week Low | $3.03 | $10.65 |
| 52 Week High | $20.79 | $17.86 |
| Indicator | RLAY | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 67.09 | 57.03 |
| Support Level | $12.10 | $10.68 |
| Resistance Level | N/A | $15.74 |
| Average True Range (ATR) | 1.31 | 0.81 |
| MACD | 0.17 | -0.04 |
| Stochastic Oscillator | 85.38 | 60.61 |
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.